{"ticker": {"uuid": "b5fd8ad1-8781-46c7-8f7d-d55f3271cea4", "symbol": "LIMN", "name": "Liminatus Pharma, Inc. Class A Common Stock", "exchange": "NASDAQ", "country": "US", "sector": "Healthcare", "industry": "Biotechnology"}, "articles": [{"title": "$Liminatus Pharma (LIMN.US)$", "summary": "", "url": "https://news.google.com/rss/articles/CBMihAFBVV95cUxQd01zWDhQRmFXQm9yNjdjWHlwdmVNbGJUNzI4YjQzNC1YU3dfdk9ER0p6ZlRVT1R0QnJLN2FrS2llTUN0Z09FUHZ4MjMwODhnWnJkR1NrdERGeXM2cUtRWVllLWtqQ1FCZm55d3Ntb0xqV1lWWW9hd0dROHVpNDYwSm5CNVc?oc=5", "source_name": "Moomoo", "published_at": "2026-07-20T07:00:00+00:00", "published_display": "20 Jul 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Enterprise value to EBITDA forward of Liminatus Pharma, Inc. \u2013 BOATS:LIMNW", "summary": "This article provides financial information for Liminatus Pharma, Inc. (LIMNW) on TradingView, specifically focusing on its enterprise value to EBITDA forward. It indicates that no trades have occurred and the market is closed for this stock. The page is primarily a financial dat", "url": "https://www.tradingview.com/symbols/BOATS-LIMNW/financials-statistics-and-ratios/enterprise-value-ebitda-fwd/", "source_name": "TradingView", "published_at": "2026-07-19T10:43:07", "published_display": "19 Jul 2026 10:43", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to earnings forward of Liminatus Pharma, Inc. \u2013 BOATS:LIMNW", "summary": "The article mentions the \"Price to earnings forward\" for Liminatus Pharma, Inc. (BOATS:LIMNW) and indicates that the market is currently closed with no trades. It appears to be a financial data snippet from a trading platform, potentially TradingView, listing basic company and ma", "url": "https://www.tradingview.com/symbols/BOATS-LIMNW/financials-statistics-and-ratios/price-earnings-fwd/", "source_name": "TradingView", "published_at": "2026-07-18T17:39:18", "published_display": "18 Jul 2026 17:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Q1 Earnings Highs And Lows: Natera (NASDAQ:NTRA) Vs The Rest Of The Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMilAFBVV95cUxNYmZ3aHMyMjBuNmlEUGN6NWZBZV85cEFWNndJaVNoNEVYNk84MlNKRXJ0RXpRQl9wN1RsekhxM3loY1RRNDJhTnVremtReHhLQWVHS053VzRBUTduSkdqRGt1YkxMMThqZHoydElPX1Zfd3hEMi15VlRwRGRvZ2JqRDFneVVxN0JCYzQ4QlV5TTBEOWx3?oc=5", "source_name": "Market source", "published_at": "2026-07-16T18:49:22+00:00", "published_display": "16 Jul 2026 18:49", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Why Did Vir Biotechnology Stock Surge 60% After-Hours Today?", "summary": "", "url": "https://news.google.com/rss/articles/CBMiuwFBVV95cUxPSGpqV09Qc0RwZVU4cm1RODdrSUJFdWNYYmw5ZVNMTmhDRVhCTm15aTZSajhRckF6R194Q1hqTjZKQXJlbmJDMC1XT21TRDVfZ2xidWd4NzdxVE5oV1RURFhRMkFqajJUTnRQWm1GeUp6V1VJMzdKTzh0OGczWkp4M1VzdmR5Um43dVlSVnF2Tk1jTU9peTJvdkpHQUNjNlpSSmp0UEZwSWwzcnZZSUtJbVdiNnREOGtpaThF?oc=5", "source_name": "Stocktwits", "published_at": "2026-07-16T18:18:54+00:00", "published_display": "16 Jul 2026 18:18", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "12 Health Care Stocks Moving In Thursday's Intraday Session", "summary": "This article identifies 12 health care stocks that experienced significant price movements during Thursday's intraday trading session. It highlights both gainers, such as Liminatus Pharma and Agape ATP, and decliners, including Alpha Compute and Senti Biosciences, detailing their", "url": "https://www.benzinga.com/trading-ideas/movers/26/07/60505873/12-health-care-stocks-moving-thursday-s-intraday-session", "source_name": "Benzinga", "published_at": "2026-07-16T16:41:06", "published_display": "16 Jul 2026 16:41", "sentiment": "positive", "sentiment_pct": 72, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Liminatus Pharma (LIMN) Stock Is Trending Overnight \u2014 Here\u2019s Why it Spiked Over 30% in After-Hours Session", "summary": "Liminatus Pharma (LIMN) stock surged over 30% in after-hours trading following an amendment to its merger agreement with InnocsAI LLC. The revised structure allows the deal to close quickly, with InnocsAI equity holders receiving a combination of Liminatus common and non-voting c", "url": "https://www.sahmcapital.com/news/content/liminatus-pharma-limn-stock-is-trending-overnight-heres-why-it-spiked-over-30-in-after-hours-session-2026-07-02", "source_name": "Sahm", "published_at": "2026-07-15T20:43:07", "published_display": "15 Jul 2026 20:43", "sentiment": "positive", "sentiment_pct": 67, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 85, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Form 13D/A Liminatus Pharma For: 14 July By Investing.com", "summary": "This article announces the filing of Form 13D/A for Liminatus Pharma on July 14, indicating a significant disclosure related to the company. It briefly mentions the stock symbol LIMN and its price performance, but provides no further details on the content of the filing itself. T", "url": "https://ng.investing.com/news/stock-market-news/form-13da-liminatus-pharma-for-14-july-93CH-2599664", "source_name": "Investing.com Nigeria", "published_at": "2026-07-15T10:12:27", "published_display": "15 Jul 2026 10:12", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Form 4 Liminatus Pharma Inc For: 14 July By Investing.com", "summary": "This article from Investing.com reports on a Form 4 filing for Liminatus Pharma Inc, dated July 14, 2026. Form 4 filings are used to report changes in beneficial ownership of securities by company insiders. The article indicates that Liminatus Pharma Inc (LIMN) saw a 15.36% incre", "url": "https://ng.investing.com/news/stock-market-news/form-4-liminatus-pharma-inc-for-14-july-93CH-2599673", "source_name": "Investing.com Nigeria", "published_at": "2026-07-14T22:52:00", "published_display": "14 Jul 2026 22:52", "sentiment": "positive", "sentiment_pct": 58, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Liminatus Pharma (LIMN) investors Valetudo and Chris Kim report 9.6M-share stake", "summary": "", "url": "https://news.google.com/rss/articles/CBMiygFBVV95cUxOYWJyVzJFenlzZ0xoNkx5T0tqZTN5UU1BdVgwcUNzVUNDMnpDTlZvd0g5QUlpNnBoRzR5MVVHQUhJR0M2M1I5dWIzMk5jWnQ1b2VncGVhLXJ6b19qMWRMSG5CSVcxUjBaR1Z1VEo2Z0kwbDZaZUoyQ3FyZWxLZGttZ0JaOTRTMnZycDNxcWRoTk90NVhWQ1VEOTN3TFBNMHlobDJaV2F5YWREOXM0YmxzY0NnNzl1blhOT3lpRGxWTm4zVFVYUTZCOFZ3?oc=5", "source_name": "Stock Titan", "published_at": "2026-07-14T21:36:44+00:00", "published_display": "14 Jul 2026 21:36", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Form DEF 14A Liminatus Pharma Inc For: 13 July By Investing.com", "summary": "This article reports on the filing of Form DEF 14A by Liminatus Pharma Inc. on July 13th, as published by Investing.com. It indicates Liminatus Pharma Inc. (LIMN) stock is down 8.30%. The content is brief, primarily acting as an announcement of the regulatory filing and its date.", "url": "https://ng.investing.com/news/stock-market-news/form-def-14a-liminatus-pharma-inc-for-13-july-93CH-2596939", "source_name": "Investing.com Nigeria", "published_at": "2026-07-13T13:50:00", "published_display": "13 Jul 2026 13:50", "sentiment": "negative", "sentiment_pct": 31, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Unpacking Q1 Earnings: Incyte (NASDAQ:INCY) In The Context Of Other Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMinAFBVV95cUxOZExLRk1BSFNPMnpMdEFEWjNtbWlkZUQ1aHJHZEtMZHJHZWZDZUI0ck1FM2JqWG9ncDRSNGxEWHZLemZualBEY3BVVzdiUmZiVmxqMFdnbEczbEpvTFBscnA3YVVMWmQ3TkFsVjBDZzl6VEZQanh1UkRaS2hiRTNPbGFwajRSV1A1amFKcnFhcFVITHdydjJpblVRTWI?oc=5", "source_name": "Market source", "published_at": "2026-07-13T12:30:39+00:00", "published_display": "13 Jul 2026 12:30", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Teleflex Incorporated (TFX) Stock Analysis: Unpacking a 32.3% Revenue Growth in the Healthcare Sector", "summary": "", "url": "https://news.google.com/rss/articles/CBMi4gFBVV95cUxPQ3B5MlVsTlBhcXdmUVllazV2SWFHTmRudHVNdFY3RUYtR1FTXzNIV1VYODF0bTMyVThkOE1LZC11TGN2dUxBZzRPTDQxUDVDdF9PWW5VUk1rZVJkdXRjbTQ2MU1wa3BtejZ5NUhWY1dQLUZLS3duak1fMzIxcnNwUmc4X3N5Q1JXMFNQY1J0ZVd5aHF4NHVUQkpnNlNUU1VWcVljNjhGbkFicUNyOXktR0lZWkVxT09oU0VQZnZObG5RMkJDWHh4czRrUktNZFNrZVhKWnF1YTZ2ZmVzTG14WG1n?oc=5", "source_name": "DirectorsTalk Interviews", "published_at": "2026-07-13T09:24:17+00:00", "published_display": "13 Jul 2026 09:24", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to sales forward of Liminatus Pharma, Inc. \u2013 NASDAQ:LIMNW", "summary": "The article displays the \"Price to sales forward\" metric for Liminatus Pharma, Inc. (NASDAQ: LIMNW) within the TradingView platform. It shows that there are no trades and the market is closed for this specific financial metric. The content highlights the navigation path to this i", "url": "https://www.tradingview.com/symbols/NASDAQ-LIMNW/financials-statistics-and-ratios/price-sales-fwd/", "source_name": "TradingView", "published_at": "2026-07-12T13:10:47", "published_display": "12 Jul 2026 13:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to sales forward of Liminatus Pharma, Inc. \u2013 NASDAQ:LIMN", "summary": "The article displays the \"Price to sales forward\" metric for Liminatus Pharma, Inc. (LIMN) on the Nasdaq Stock Market. It indicates that the market was closed at the time of viewing, with no trades observed. The content primarily shows the financial information section for the co", "url": "https://www.tradingview.com/symbols/NASDAQ-LIMN/financials-statistics-and-ratios/price-sales-fwd/", "source_name": "TradingView", "published_at": "2026-07-11T23:10:32", "published_display": "11 Jul 2026 23:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Enterprise value to EBIT forward of Liminatus Pharma, Inc. \u2013 NASDAQ:LIMN", "summary": "This article focuses on the enterprise value to EBIT forward metric for Liminatus Pharma, Inc. (NASDAQ: LIMN). It appears to be a financial data point provided on a trading platform, likely TradingView, indicating a specific financial ratio for the company's valuation.", "url": "https://www.tradingview.com/symbols/NASDAQ-LIMN/financials-statistics-and-ratios/enterprise-value-ebit-fwd/", "source_name": "TradingView", "published_at": "2026-07-09T20:13:18", "published_display": "09 Jul 2026 20:13", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Liminatus Pharma, Inc. Class A Common Stock (NASDAQ: LIMN) Stock Price, News & Analysis", "summary": "This article provides an overview of Liminatus Pharma, Inc. (NASDAQ: LIMN) stock, including its current price, basic fundamental data, and a link to charting information. It highlights the stock's last updated price of $0.123 and discusses its low trading volume. The page also of", "url": "https://kalkine.com.au/company/nasdaq-limn/", "source_name": "Kalkine", "published_at": "2026-07-09T20:13:18", "published_display": "09 Jul 2026 20:13", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Number of employees of Liminatus Pharma, Inc. \u2013 NASDAQ:LIMNW", "summary": "This article focuses on Liminatus Pharma, Inc. (NASDAQ: LIMNW) and specifically addresses the number of its employees. It appears to be a stub or data-point-oriented page from TradingView, which aggregates financial data for the company.", "url": "https://www.tradingview.com/symbols/NASDAQ-LIMNW/financials-statistics-and-ratios/number-of-employees/", "source_name": "TradingView", "published_at": "2026-07-08T13:11:04", "published_display": "08 Jul 2026 13:11", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Enterprise value to EBITDA forward of Liminatus Pharma, Inc. \u2013 NASDAQ:LIMN", "summary": "This article provides financial data for Liminatus Pharma, Inc. (NASDAQ: LIMN), focusing on its enterprise value to EBITDA forward metric. The content highlights the company's stock market information on Nasdaq and lists various financial and community services offered by Trading", "url": "https://www.tradingview.com/symbols/NASDAQ-LIMN/financials-statistics-and-ratios/enterprise-value-ebitda-fwd/", "source_name": "TradingView", "published_at": "2026-07-08T01:10:35", "published_display": "08 Jul 2026 01:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "4.37M Liminatus (NASDAQ: LIMN) shares moved in entity transfer", "summary": "Valetudo Therapeutics LLC, a ten percent owner of Liminatus Pharma (NASDAQ: LIMN) and associated with CEO Chris Kim, transferred 4,373,603 shares of common stock to Ewon Comfortech Co., Ltd. for no consideration. Valetudo retains voting power over these transferred shares through", "url": "https://www.stocktitan.net/sec-filings/LIMN/form-4-liminatus-pharma-inc-insider-trading-activity-a09731f15256.html", "source_name": "Stock Titan", "published_at": "2026-07-07T17:11:04", "published_display": "07 Jul 2026 17:11", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Ewon Comfortech discloses 5.5M shares in Liminatus Pharma (NASDAQ: LIMN)", "summary": "Ewon Comfortech Co., Ltd. has disclosed a beneficial ownership of 5.5 million shares, representing 10.9% of Liminatus Pharma Inc. (NASDAQ: LIMN) common stock, according to a Schedule 13G/A filing. The filing indicates Ewon Comfortech holds sole dispositive power over all 5.5 mill", "url": "https://www.stocktitan.net/sec-filings/LIMN/schedule-13g-a-liminatus-pharma-inc-amended-passive-investment-disclo-0a686970482a.html", "source_name": "Stock Titan", "published_at": "2026-07-07T05:10:35", "published_display": "07 Jul 2026 05:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Liminatus Pharma (LIMN) completes InnocsAI acquisition with large convertible preferred stake", "summary": "Liminatus Pharma has completed its acquisition of InnocsAI by restructuring the merger consideration to include both common stock and a significant stake in new Series A Non-Voting Convertible Preferred Stock. This strategy allowed the deal to close before obtaining full stockhol", "url": "https://www.stocktitan.net/sec-filings/LIMN/8-k-liminatus-pharma-inc-reports-material-event-e74c8b54791f.html", "source_name": "Stock Titan", "published_at": "2026-07-07T05:10:35", "published_display": "07 Jul 2026 05:10", "sentiment": "negative", "sentiment_pct": 34, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 96, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to earnings forward of Liminatus Pharma, Inc. \u2013 NASDAQ:LIMN", "summary": "This article provides the \"Price to earnings forward\" value for Liminatus Pharma, Inc. (NASDAQ: LIMN). It indicates that the value is currently not available, with no trades recorded. The content seems to be a placeholder or a very early stage financial data page for the company ", "url": "https://www.tradingview.com/symbols/NASDAQ-LIMN/financials-statistics-and-ratios/price-earnings-fwd/", "source_name": "TradingView", "published_at": "2026-07-07T03:40:41", "published_display": "07 Jul 2026 03:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Form 4 Liminatus Pharma Inc For: 6 July By Investing.com", "summary": "This article reports on a Form 4 filing for Liminatus Pharma Inc which took place on July 6th. Form 4 filings are regulatory documents that must be filed with the U.S. Securities and Exchange Commission (SEC) whenever there is a material change in the holdings of company insiders", "url": "https://ng.investing.com/news/stock-market-news/form-4-liminatus-pharma-inc-for-6-july-93CH-2587705", "source_name": "Investing.com Nigeria", "published_at": "2026-07-06T22:04:00", "published_display": "06 Jul 2026 22:04", "sentiment": "negative", "sentiment_pct": 29, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to book forward of Liminatus Pharma, Inc. \u2013 NASDAQ:LIMN", "summary": "", "url": "https://news.google.com/rss/articles/CBMinAFBVV95cUxPbC12d1BpMWc2cTJ3Y3NYREVIWm5yUjFCLXplUmJfY2FCalZCUk9tRzFteExURUVjNXJYYXM2aUZILVpzTVNWZnVYMVQ5MFJHUDZobmp4RnlDa0FnZjE4b3MzaUVNOXg0ZFlSaHJXSDZfVS1kcF85VlBuTE9VUjdMVEtFb3UyWVAxblpXQTFWa0F6MjIxRGlvc3FwaHU?oc=5", "source_name": "TradingView", "published_at": "2026-07-05T23:39:13+00:00", "published_display": "05 Jul 2026 23:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Tenet Healthcare Stock Jumps As Analysts Hold Buy Ratings Into Earnings", "summary": "", "url": "https://news.google.com/rss/articles/CBMiiAFBVV95cUxNYzlxZUxqQXJsWHRaUDE4SE1xeXUySXpBalJOamFXdlpnOHdQU25fTVFSdGZlcENQX2tLU2ljMXlvNW8xSnFNcHhsYnhJZURQSWNueTR4cVItWVdxbXFOeDNWYVRfOG9rWGpBNUUwT2lBSHVkcFdMdnhEUzdycnczUms3a3dzSDk5?oc=5", "source_name": "timothysykes.com", "published_at": "2026-07-04T07:00:00+00:00", "published_display": "04 Jul 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "LIMN - Liminatus Pharma Inc Options", "summary": "This article provides a detailed financial overview of Liminatus Pharma Inc. (LIMN), including its market capitalization, income, sales, key valuation ratios, and stock performance metrics. It covers various operational and financial statistics, such as insider and institutional ", "url": "https://finviz.com/stock?t=LIMN&ty=oc&p=d&b=1", "source_name": "Finviz", "published_at": "2026-07-04T04:09:03", "published_display": "04 Jul 2026 04:09", "sentiment": "positive", "sentiment_pct": 60, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Biotech Pre-Market Pulse: LIMN, TENX, ELTX Swing Big", "summary": "Several biotech companies are showing significant gains in pre-market trading, indicating early momentum for the day. Liminatus Pharma (LIMN), Tenax Therapeutics (TENX), and Conexeu Sciences (CNXU) are among the leading gainers. The article details the top 10 pre-market biotech s", "url": "https://www.rttnews.com/3664349/biotech-pre-market-pulse-limn-tenx-eltx-swing-big.aspx", "source_name": "RTTNews", "published_at": "2026-07-02T13:41:11", "published_display": "02 Jul 2026 13:41", "sentiment": "positive", "sentiment_pct": 68, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "12 Health Care Stocks Moving In Thursday's Pre-Market Session", "summary": "This article lists 12 healthcare stocks experiencing significant movement in Thursday's pre-market session. It details both gainers like Liminatus Pharma (NASDAQ:LIMN) and Stablecoin Development (AMEX:SDEV), and decliners such as Elicio Therapeutics (NASDAQ:ELTX) and Beyond Air (", "url": "https://www.benzinga.com/trading-ideas/movers/26/07/60241536/12-health-care-stocks-moving-thursday-s-pre-market-session", "source_name": "Benzinga", "published_at": "2026-07-02T11:41:11", "published_display": "02 Jul 2026 11:41", "sentiment": "positive", "sentiment_pct": 75, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Why Tenet Healthcare (THC) Stock Is Up Today", "summary": "", "url": "https://news.google.com/rss/articles/CBMipgFBVV95cUxNTGpMSWYxM2M3RmxZNHFVMm5pTnNfeTZKNzNiWHFJRTBkUDYtMWJaOFB0ZUVKYldFclQ2WFdscFJKTjdHS25XZVpMRE9CRUlSU3NDS3hKTUtaamxpREN2LTAyc3AtdWdTZlhzZ3kzYmEtMEI5QjVGZ0VVdFN2R0dKUWh2Vm9FelByMUU5N0tXQk5OeU5ZZndqekVNeEJVbHVZVTNUdmFB?oc=5", "source_name": "TradingView", "published_at": "2026-07-02T07:00:00+00:00", "published_display": "02 Jul 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Press Release: Liminatus Pharma Amends Definitive Merger Agreement With InnocsAI to Expand Oncology Cell Therapy Pipeline", "summary": "Liminatus Pharma has amended its definitive merger agreement with InnocsAI, acquiring an exclusive global license for InnocsAI's AI-driven oncology cell therapy programs. This strategic move is expected to expand Liminatus's pipeline, particularly in areas like breast cancer and ", "url": "https://www.moomoo.com/news/post/72285085/press-release-liminatus-pharma-amends-definitive-merger-agreement-with-innocsai", "source_name": "Moomoo", "published_at": "2026-07-01T14:41:11", "published_display": "01 Jul 2026 14:41", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Liminatus Pharma Amends Merger Deal With InnocsAI", "summary": "", "url": "https://finance.yahoo.com/markets/stocks/articles/liminatus-pharma-amends-merger-deal-112501129.html", "source_name": "MT Newswires", "published_at": "2026-07-01T11:25:01+00:00", "published_display": "01 Jul 2026 11:25", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 85, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Form PRE 14A Liminatus Pharma Inc For: 30 June By Investing.com", "summary": "This article announces the filing of Form PRE 14A by Liminatus Pharma Inc for June 30. It is a brief, factual update from Investing.com, providing basic financial market data alongside the news. The filing itself is not detailed, but the article contextualizes it within a broader", "url": "https://ng.investing.com/news/stock-market-news/form-pre-14a-liminatus-pharma-inc-for-30-june-93CH-2579596", "source_name": "Investing.com Nigeria", "published_at": "2026-07-01T03:39:19", "published_display": "01 Jul 2026 03:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Liminatus Pharma Amends Definitive Merger Agreement with InnocsAI to Expand Oncology Cell Therapy Pipeline", "summary": "Liminatus Pharma, Inc. has amended its definitive merger agreement with InnocsAI LLC, an oncology biotechnology company, to strategically expand its oncology cell therapy pipeline. The re-structured transaction, now valued at approximately $320 million, is expected to close on Ju", "url": "https://www.manilatimes.net/2026/07/01/tmt-newswire/globenewswire/liminatus-pharma-amends-definitive-merger-agreement-with-innocsai-to-expand-oncology-cell-therapy-pipeline/2376263/amp", "source_name": "The Manila Times", "published_at": "2026-07-01T02:36:00", "published_display": "01 Jul 2026 02:36", "sentiment": "positive", "sentiment_pct": 76, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Liminatus amends InnocsAI merger, closing set for July 2", "summary": "Liminatus Pharma, Inc. has amended its merger agreement with InnocsAI LLC, with the closing now expected on July 2, 2026. The revised terms involve InnocsAI equity holders receiving Liminatus common stock and non-voting convertible preferred stock, valued at approximately $320 mi", "url": "https://www.investing.com/news/company-news/liminatus-amends-innocsai-merger-closing-set-for-july-2-93CH-4768848", "source_name": "Investing.com", "published_at": "2026-06-30T21:39:28", "published_display": "30 Jun 2026 21:39", "sentiment": "negative", "sentiment_pct": 19, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Liminatus pushes $320M InnocsAI merger to July 2 close", "summary": "Liminatus Pharma (Nasdaq: LIMN) has amended its definitive merger agreement with InnocsAI, restructuring the $320 million transaction to close on July 2, 2026, before obtaining stockholder approval. InnocsAI equity holders will receive Liminatus common and non-voting convertible ", "url": "https://www.stocktitan.net/news/LIMN/liminatus-pharma-amends-definitive-merger-agreement-with-innocs-ai-6el3l58pczox.html", "source_name": "Stock Titan", "published_at": "2026-06-29T18:10:47", "published_display": "29 Jun 2026 18:10", "sentiment": "positive", "sentiment_pct": 60, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Cooper Companies Stock: Is COO Underperforming the Healthcare Sector?", "summary": "", "url": "https://news.google.com/rss/articles/CBMiqwFBVV95cUxPWkdoUDRJdkh3QndoZ3J2OHBvOEJlMUFEYjc1X3pLZGFXUlJ6eS1iNXhpYzNyd1NSZGxPOUdDM0xnZW9RcS1kdWNwR0xydVFVcEFGVmhfWWF5SFhYTmR5dXM0cTRIUENtbTc5bUpuNTNZQ0h0QWhMbnZDdGpfYjRWM2c3SWlCOHVJYTVoaUdDYnk2cTRKWWZTZHFvXzZDMTFmOGRUUUhyX3J6RUE?oc=5", "source_name": "Market source", "published_at": "2026-06-16T07:00:00+00:00", "published_display": "16 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Puma Biotechnology Stock Rises 19% in 3 Months: Here's Why", "summary": "", "url": "https://news.google.com/rss/articles/CBMinwFBVV95cUxObTdhSlJXM3BhWXRZM1NuWVBvNFZKS09CUkMyLV93TEdVQUdycktzUG5tRnFwUFlabkluMDFsMUpYYzFiQUxPWVdwczhNeVVjN0Rvc2k3VUZuS3NlTmEycHVpMGV1eDhnaEZkQ1JCaHVkcVZnMGd6Q2xzYnVpZV9tVVRLcjZnaWd0NlRhSnRENWIxSzhBQkd5WnRxVXN4dkk?oc=5", "source_name": "Market source", "published_at": "2026-06-11T07:00:00+00:00", "published_display": "11 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Liminatus Pharma Enters Into Warrant Exercise Transaction for $1.9 Million in Gross Proceeds", "summary": "", "url": "https://finance.yahoo.com/markets/stocks/articles/liminatus-pharma-enters-warrant-exercise-123000210.html", "source_name": "GlobeNewswire", "published_at": "2026-06-03T12:30:00+00:00", "published_display": "03 Jun 2026 12:30", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Existing investors put $1.9M into Liminatus in 18\u00a2 warrant deal", "summary": "", "url": "https://news.google.com/rss/articles/CBMivAFBVV95cUxObjhnY1FkWHVWVkFJNWxMT25BU1hWMkliNFJnYXNuWmVZNFUyUm95ZGY0MTJvU19vUW9YOGcyNG9nUzIwQjZ0N1hqMlJQRWc1Tzh6bDd1eXRYZi1od2xKUW5DeERBcHM4cHgxVWpPZkhYQVVJX01MbDJCQkh2eURJcDRveGdpclFib1oxM3N0NXJ1RHh1elNnS3pGN1htQjZKRTY5U0FGRm9yTjZZTzdyVnhXUndyN1pnS2hFcg?oc=5", "source_name": "Stock Titan", "published_at": "2026-06-03T07:00:00+00:00", "published_display": "03 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "UNH stock jumps on Q1 earnings beat and raised guidance to $18.25+", "summary": "", "url": "https://news.google.com/rss/articles/CBMimAFBVV95cUxPTEprdzNMNGZxdkg5Wll5MTlvS1dheXQybm14TERTcGVzcHQzY0llOEpTa0dpZ1hGdHVyNWZ2cFFiWmZRdkl1aUp4YVlTMVJxSDRzaEdzRFB1cW93QzdhSmNxcEZDMWhGX2F0ODJFcjY1Mk1kMVhLNnVJSUhVMHZpRjRtTHo2cXBvbVJ3a05SWlJNMUdrSzFPbA?oc=5", "source_name": "eciks.org", "published_at": "2026-05-26T07:00:00+00:00", "published_display": "26 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 84, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Liminatus Pharma, Inc. Receives Nasdaq Delisting Notice Following Non-Compliance with Market Value Requirements", "summary": "", "url": "https://news.google.com/rss/articles/CBMi3AFBVV95cUxQYXdNZFdFaUhJaGhmOV9LYXhaS055ZzBXNlhPaFVjOW1uNHd6bndtM1NQX2hzSFgxem5RcE9aYVZXdzZwRll4UUtzbHYwbXVDVVJ6UkdMUnpPdjQ4QmhaY1FNLTdtUFRaRXJnWGhFT1V5MFJ6dXlkbjVaNllkQnoyUE9xUHQ3c0lKT3pQOC1SeXVkUjktaUtCbklhTVNWU0pRR25oTFNSTldXQS1NazNJaFFvSUJ1akhObmszbnRHeGtmbTg1TVUtbU41THZuWVhCaVM3c0VGVlRuRzU5?oc=5", "source_name": "Quiver Quantitative", "published_at": "2026-05-22T07:00:00+00:00", "published_display": "22 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Liminatus Pharma faces Nasdaq delisting after compliance failure By Investing.com", "summary": "", "url": "https://news.google.com/rss/articles/CBMiwwFBVV95cUxOeWhITjdGNV96TTZrRkJRU2hDYjJhTmZCNG1KS25tZnJ6bnNmX3oxMEsyNXpNdXFuSXVPeGE3QXR6d0ZkMVFRaHU5VDdMbXljbzlvaU92YjlYMURzcXBpb2VKeVZ0c1BhdUNhYUJfWkRzN2d2Wld0RzdYRTlUcmpfcHU2RGhKdWR1aXAtN2Q1a3FJQ0doeXg1cTk4V0w4bXNoNGhKWlVJWHVOTWh5OVIyc3lrd2dUMnNZTkZ6M2FjcTUxSEU?oc=5", "source_name": "Investing.com Nigeria", "published_at": "2026-05-22T07:00:00+00:00", "published_display": "22 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Liminatus Pharma Announces Nasdaq Delisting Notification", "summary": "", "url": "https://finance.yahoo.com/markets/stocks/articles/liminatus-pharma-announces-nasdaq-delisting-002800076.html", "source_name": "GlobeNewswire", "published_at": "2026-05-22T00:28:00+00:00", "published_display": "22 May 2026 00:28", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Trending Stocks Today | Liminatus Pharma Surges 62.75%", "summary": "", "url": "https://news.google.com/rss/articles/CBMimAFBVV95cUxQeDZ3djRLYU9mUjRkZkJXSE01X1VEalJyOWFYaFBoOXBRWFlkTm5WZjNBaVZKaHRnRmlKc2ZHd3pBVWJfVEJ4eUlTeDE3cEZYRDVSWFoxRERBUEx5R3MzM1VVY2VWd25jbUIzOV9kTngxeGh6dXYzcjBNUHBQVUxNWFdnaDRwYjVSWXZNNHpYOV9Fa2RYc3A1NQ?oc=5", "source_name": "Moomoo", "published_at": "2026-05-21T07:00:00+00:00", "published_display": "21 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Cancer biotech Liminatus lines up $320M deal for new cell therapies", "summary": "", "url": "https://news.google.com/rss/articles/CBMivwFBVV95cUxPd05HR3VqSHo0TnRJd2NqWS14ZmsxU2pFMGZxQ004NVRxTXVudmhkX2dpRUZLbFJzZ1kyMXNrRnNCV3A0Z29SSm5hNkRiSG5DUVAwSG5ieGdsUUlybVhFdXcwX2tTTXNyanJ2QXBmTG1uMFZvLVJiMnJKWDgyeDJTc25fWlJFeEZSNXgtR01OLUcyRjh5RkYzWE5TYmktNGkwUm02YVNXVW5peFRWRGpKZG0wZlplU25XR3p4X1Q3MA?oc=5", "source_name": "Stock Titan", "published_at": "2026-05-21T07:00:00+00:00", "published_display": "21 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Liminatus Pharma Is Trending Overnight \u2014 Here's Why LIMN Stock Surged Over 79% In After-Hours Session", "summary": "", "url": "https://news.google.com/rss/articles/CBMi6gFBVV95cUxPeWdyd09vdXhDTFdUYXV3SG0wZGtPRmFWR1AzTW1OemRGRlhsT0VoNFNRSEdrWGJLdGNpR09XLVowWG1KdVpHalpiaXNwLWtjOTBJTFctZVBMZktOVkpWbjc2WkJpQVY5d3M4ZVhZVFdOaGtlR1R2UGliNjNaZy03VkwwSkdXalNsZU5rNzVWNUtUbk5zTWM4NkNocnZCSzlWQ29ybHZ3eHVFaEUwVnpTZ2J4R2lTUFFVclloaGhpNFMxS1JNNmVyZ2JPWjdXTzNYUzdwZHhDbUFOVmpkZ3h4ZHpucVA3VWlXLUE?oc=5", "source_name": "Benzinga", "published_at": "2026-05-21T07:00:00+00:00", "published_display": "21 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Liminatus Pharma faces Nasdaq delisting after market value shortfall", "summary": "", "url": "https://news.google.com/rss/articles/CBMinwFBVV95cUxOTURCcG1UY1JheVlhTWZuNElsNzRGLVYwaGNfdmxsUkRiSmhaTHlHUzIyRkVyU3JaS3R5c0VPU2dZYlZhZVpYcUpGc2J2YXc2UHdGUjhtYXVuZ2gtaUgwS3FNSGNpbGxVZGxMeFktZFYyWkx2LW02S2o0YzctVUlEM2cweGpfaXAzOHJsVm93U3dyNlVZMFBLNGxNTlZmV2M?oc=5", "source_name": "Stock Titan", "published_at": "2026-05-21T07:00:00+00:00", "published_display": "21 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Liminatus Pharma (LIMN) plans all-stock InnocsAI merger with CAR-T pipeline", "summary": "", "url": "https://news.google.com/rss/articles/CBMirgFBVV95cUxPT21KRjM0Zm02cEpwVkQwZWQ3Z1NPTExjZFlMZ1ZnZDVfV3FpVlVYalZmeG1KYlVtQkQ0NFhDN3RVMU5GQXp2aW5ScF82N2N0U3kzcThJc3dIYnJOeW1YbzljalFpX1JnMGpLQXJ0T09sYndTZHNzM2FaZUdXZGJLMzR0ZnJMTkVpR1JiVjRRcmx3d1NCNFVqVS12TXRpdEhiUHhVOXZjN2hTU28tZHc?oc=5", "source_name": "Stock Titan", "published_at": "2026-05-20T07:00:00+00:00", "published_display": "20 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "There May Be Reason For Hope In Puma Biotechnology's (NASDAQ:PBYI) Disappointing Earnings", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-15T07:00:00+00:00", "published_display": "15 May 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Puma Biotechnology's (NASDAQ:PBYI) Conservative Accounting Might Explain Soft Earnings", "summary": "", "url": "https://news.google.com/rss/articles/CBMirgFBVV95cUxNZXcyN1VKc0J0RTFtSER6TGRSZm8xSWs2c0paem5paDd3V0J1cjF6ajhFb29tRFpUWWpxYUhzZjFkSXhYQ0lBNTVlbTdCRERpSXNjaGpDajFPOVlpRS1qV2xHMTRHS2pjVVBZMWFfNzItWE9FeENtQ2duMUxVQm5kOG41eVlrNUpObXp2VlhfekdhMVh2X0hjN3ZFZThZNUdWakFLUXJ4aFBVN2JyR2c?oc=5", "source_name": "Market source", "published_at": "2026-05-14T07:00:00+00:00", "published_display": "14 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Puma Biotechnology, Inc. (NASDAQ:PBYI) Analysts Are Pretty Bullish On The Stock After Recent Results", "summary": "", "url": "https://news.google.com/rss/articles/CBMi5wFBVV95cUxOWWM3V1pmZzdlY1llRTljQmNLQ2UwdDdQaFVEcng2WVdrNE9qNzRrNVpBVlJNMGltQUhBUG1qellCVHNiM09fUkFHRW1kMEpvazJoLU11N3c4YnlWUXpmVl82aWNKeTA4U1RwSHNNSVd4d0lwWHRJclQ2TGNHWUpBQTgzbTBMVk05VGxYN0RwcmpTYklOQUFSWDhsSHZlQVpndmlPRGNvTmRmeHNILWg4ZE5jMjRoN01XNENiaVU2UDUyOWJfYUZCTm5URmtwTHJsTjJYNHo3RkxsQjBSMnBmdVZVWkFwN2PSAewBQVVfeXFMT3htM016bEt0TTdyOXE2amppMGpubTNfOFU4cGpxd2dFZkJDTjR3c0ZqOHpHYWZoamNLdmkxVmNYNklxTEM4NTU0bDZwUTZ1SW5Jc1c4NmRJN3lKQUVqUUNYYWptd2ZYNE9TeEhMRzFvbEt0bjk1TVhyVG44UnJnNDllTlFsalJVUTZwcEEzWXljbzdaQXdWWDlHQW56bGxqeG90UlFmaFFLekJlUlNIOVE4SGNHcE9pOW1KSllleVdwNERiaVl2NmxtNTNyaUtnSFY1VHUzcDJsWE9xb3R1ajZ2RGhkXzJzTldMOVA?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Earnings Update: Here's Why Analysts Just Lifted Their Puma Biotechnology, Inc. (NASDAQ:PBYI) Price Target To US$5.00", "summary": "", "url": "https://news.google.com/rss/articles/CBMingFBVV95cUxPSUN3RjZYMEJ2VUdKQjJpRkZaUXRzM2NTa05WWmlmWHJnZDlJeUpTdFM5Wmk0SUhjclU2dldTZFIyRmZZeGJSNGM2SUNiSGJSYjh1VjYyR0hPZ2FJbWdsbHExYlhwMW1HRTZ0NUxwQzU1b2g4MGpwSHdoMkdIOUtqOXBBYk92LVk2cEFZMzVISjB3c04ydVBEYWw2cVVsdw?oc=5", "source_name": "Market source", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Q4 Earnings Highlights: Regeneron (NASDAQ:REGN) Vs The Rest Of The Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMirAFBVV95cUxNWW9GYm5uRzlBX2ZiZXA3RkdDXzJhaFd2N1ZwR21jaXhiRkZQSTNHT0hMaUFjSGl6VXZfOURKemF2bWlFS1hKTXBjZUw4amdVQ0I4QlVnNmFkY1VTQ25pUjBiZGNDUE9QdWdOZHAxV1I1ejN6UE9WdGpseUdrMVA5MXBXWXJmWDBkZUdWUkxpOURCdlZlbDlQR3M5cjAzaDFtakFNblRTa3c0Q1J6?oc=5", "source_name": "Market source", "published_at": "2026-04-25T07:00:00+00:00", "published_display": "25 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Biotechnology Stocks Q3 Results: Benchmarking Natera (NASDAQ:NTRA)", "summary": "", "url": "https://news.google.com/rss/articles/CBMiswFBVV95cUxPZzZDSEhwNlVYQU9kNXBMMU5ia0FTU0RxRlYwb0I1RERNODN4N0VwRFZWMUY4ODh3eWNkTkp0UERreFlSTllocGk4a2ZKcGlJVjQ4d1dXWlNnYTc5UlNMZm4wc2xITjRQVzhRb3Z5LXllQmhvUHNIaXB3LXk1RUw1WnRPam9wcVE1MXFxSmVzVF9MVmRyMWIwdVkxS1N3MUJZUzByLWxrVDlSSUk4QnNsXzJYbw?oc=5", "source_name": "Market source", "published_at": "2026-04-21T07:00:00+00:00", "published_display": "21 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "A Look Back at Biotechnology Stocks\u2019 Q4 Earnings: Incyte (NASDAQ:INCY) Vs The Rest Of The Pack", "summary": "", "url": "https://news.google.com/rss/articles/CBMi5gFBVV95cUxNWEtsYkktQkxQRHpTMHJOZzJaN09fT3R5aUpjZ0xEQTZXZGlCVUk0alZrVXhIRERNOW9feVJ1X0R4VUI2Q0FjUGIwTWpIRXE2dXpCLW9NdVdoSEE5b0JEM18wN2FQSGdXMDZfOGJ3STJPUmQ2VVBIbUQ5djhTZ01RTmpxLTdKRmdhN0U3RE52N0dEUzh4VFZ5c3dDd0ppZ1VYeGc0Mm5oQlU5TGJlQldpVHpoVjlhdXZ6ek0yaTBuQV9UUjNFT19kWFZ4QVViODkwN2ppOFRQU3lHQ1IxdXhrRkFGS3E0QQ?oc=5", "source_name": "TradingView", "published_at": "2026-03-29T07:00:00+00:00", "published_display": "29 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Puma Biotechnology Stock Declines More Than 9% in a Month: Here's Why", "summary": "", "url": "https://news.google.com/rss/articles/CBMijAFBVV95cUxNTTJZRVF4TFNBb3BhMW9VUnBnMVZhenZLNlZJY3Ryc3pGZ3dhZXBDY3pId0I5NFdmVTdiR2EyNXNBZFFuQ1M2M3pUTlRZdXJkbGxaT29mWm4wTG5fU2RtV1hIZWRwZUVNb3BEbTZKX3NPRV9mZVpiY3JBZDdMSDRveW1Jb0lIVmRKLVlidA?oc=5", "source_name": "Market source", "published_at": "2026-03-18T07:00:00+00:00", "published_display": "18 Mar 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Why Did Puma Biotechnology's Stock Plummet Despite Beating Q4 Estimates", "summary": "", "url": "https://news.google.com/rss/articles/CBMiqgFBVV95cUxQUEQ4TXY0R1lWMTJIcEJySm5iaEl1UkJ6TDMxcUtQYVl3UmxYdlJnaElpdlJDLU0xTTRvT0dsellqX21Tc3lxWW9IbWxHMnFBZGlxajdnUUU2OTNVY0l3NUh0OExMUENwWGxqY1d5dXV3YmRDZm9IRzc1c3FjbUh2cGxvdEJMZ25lYXdjSUliZ0txSjVFOHJhUXNTajBLeVV0M3B4dDk4V3dfQQ?oc=5", "source_name": "Kavout | AI", "published_at": "2026-02-28T09:53:07+00:00", "published_display": "28 Feb 2026 09:53", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Cava Stock Surges 24% After Upbeat Earnings and Strong 2026 Outlook", "summary": "", "url": "https://news.google.com/rss/articles/CBMingFBVV95cUxQcV9JR0t0QUpQRWhQU0JxOGZld2wxZmNTb0ZoV05TZVBhUjRxRGF2Zno5YWRaVkxKRzNsbk8yY01fdk95S09xcV9aT0FFS1A3Zzhfd0ZLVVVRVU1jY1BiZmZ6T0drMjlfLVNXMTVBZjdtWXdNTEdHTEc2ejFqX1lTREs3eXBhbWRjaUhRWHJMZlYxWGFGZnYwOUJ2Mm9uQQ?oc=5", "source_name": "TIKR.com", "published_at": "2026-02-26T08:00:00+00:00", "published_display": "26 Feb 2026 08:00", "sentiment": "positive", "sentiment_pct": 82, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Vir Biotechnology Stock Skyrockets 65% on Positive Prostate Cancer Treatment Trial Results", "summary": "", "url": "https://news.google.com/rss/articles/CBMivwFBVV95cUxNeEtXZ1k1WGctLWZuX0tYZE5SLWN4MU5KUktLV3NobzVheFpoMkZhdFJrWTdNelAwWGxYZUswazZtMWFUaXEzY3k0QnI0TW9IMGc2UTNzUlNmR1JxZG1JbEpQM0N3N1p4blRjaGdvMExoZzJOYWF3Tk5hajJCTlprZ3dESTVEd0Y4TXhvcElNR3Bqemd3RmNKcGxwa2dSU2phak9paE53c0t3dVFVeGZic2liZ1I0UU80TEM2WUNlOA?oc=5", "source_name": "TIKR.com", "published_at": "2026-02-25T08:00:00+00:00", "published_display": "25 Feb 2026 08:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}], "by_tier": {"direct": [{"title": "$Liminatus Pharma (LIMN.US)$", "summary": "", "url": "https://news.google.com/rss/articles/CBMihAFBVV95cUxQd01zWDhQRmFXQm9yNjdjWHlwdmVNbGJUNzI4YjQzNC1YU3dfdk9ER0p6ZlRVT1R0QnJLN2FrS2llTUN0Z09FUHZ4MjMwODhnWnJkR1NrdERGeXM2cUtRWVllLWtqQ1FCZm55d3Ntb0xqV1lWWW9hd0dROHVpNDYwSm5CNVc?oc=5", "source_name": "Moomoo", "published_at": "2026-07-20T07:00:00+00:00", "published_display": "20 Jul 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Enterprise value to EBITDA forward of Liminatus Pharma, Inc. \u2013 BOATS:LIMNW", "summary": "This article provides financial information for Liminatus Pharma, Inc. (LIMNW) on TradingView, specifically focusing on its enterprise value to EBITDA forward. It indicates that no trades have occurred and the market is closed for this stock. The page is primarily a financial dat", "url": "https://www.tradingview.com/symbols/BOATS-LIMNW/financials-statistics-and-ratios/enterprise-value-ebitda-fwd/", "source_name": "TradingView", "published_at": "2026-07-19T10:43:07", "published_display": "19 Jul 2026 10:43", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to earnings forward of Liminatus Pharma, Inc. \u2013 BOATS:LIMNW", "summary": "The article mentions the \"Price to earnings forward\" for Liminatus Pharma, Inc. (BOATS:LIMNW) and indicates that the market is currently closed with no trades. It appears to be a financial data snippet from a trading platform, potentially TradingView, listing basic company and ma", "url": "https://www.tradingview.com/symbols/BOATS-LIMNW/financials-statistics-and-ratios/price-earnings-fwd/", "source_name": "TradingView", "published_at": "2026-07-18T17:39:18", "published_display": "18 Jul 2026 17:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Why Did Vir Biotechnology Stock Surge 60% After-Hours Today?", "summary": "", "url": "https://news.google.com/rss/articles/CBMiuwFBVV95cUxPSGpqV09Qc0RwZVU4cm1RODdrSUJFdWNYYmw5ZVNMTmhDRVhCTm15aTZSajhRckF6R194Q1hqTjZKQXJlbmJDMC1XT21TRDVfZ2xidWd4NzdxVE5oV1RURFhRMkFqajJUTnRQWm1GeUp6V1VJMzdKTzh0OGczWkp4M1VzdmR5Um43dVlSVnF2Tk1jTU9peTJvdkpHQUNjNlpSSmp0UEZwSWwzcnZZSUtJbVdiNnREOGtpaThF?oc=5", "source_name": "Stocktwits", "published_at": "2026-07-16T18:18:54+00:00", "published_display": "16 Jul 2026 18:18", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "12 Health Care Stocks Moving In Thursday's Intraday Session", "summary": "This article identifies 12 health care stocks that experienced significant price movements during Thursday's intraday trading session. It highlights both gainers, such as Liminatus Pharma and Agape ATP, and decliners, including Alpha Compute and Senti Biosciences, detailing their", "url": "https://www.benzinga.com/trading-ideas/movers/26/07/60505873/12-health-care-stocks-moving-thursday-s-intraday-session", "source_name": "Benzinga", "published_at": "2026-07-16T16:41:06", "published_display": "16 Jul 2026 16:41", "sentiment": "positive", "sentiment_pct": 72, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Liminatus Pharma (LIMN) Stock Is Trending Overnight \u2014 Here\u2019s Why it Spiked Over 30% in After-Hours Session", "summary": "Liminatus Pharma (LIMN) stock surged over 30% in after-hours trading following an amendment to its merger agreement with InnocsAI LLC. The revised structure allows the deal to close quickly, with InnocsAI equity holders receiving a combination of Liminatus common and non-voting c", "url": "https://www.sahmcapital.com/news/content/liminatus-pharma-limn-stock-is-trending-overnight-heres-why-it-spiked-over-30-in-after-hours-session-2026-07-02", "source_name": "Sahm", "published_at": "2026-07-15T20:43:07", "published_display": "15 Jul 2026 20:43", "sentiment": "positive", "sentiment_pct": 67, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 85, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Form 13D/A Liminatus Pharma For: 14 July By Investing.com", "summary": "This article announces the filing of Form 13D/A for Liminatus Pharma on July 14, indicating a significant disclosure related to the company. It briefly mentions the stock symbol LIMN and its price performance, but provides no further details on the content of the filing itself. T", "url": "https://ng.investing.com/news/stock-market-news/form-13da-liminatus-pharma-for-14-july-93CH-2599664", "source_name": "Investing.com Nigeria", "published_at": "2026-07-15T10:12:27", "published_display": "15 Jul 2026 10:12", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Form 4 Liminatus Pharma Inc For: 14 July By Investing.com", "summary": "This article from Investing.com reports on a Form 4 filing for Liminatus Pharma Inc, dated July 14, 2026. Form 4 filings are used to report changes in beneficial ownership of securities by company insiders. The article indicates that Liminatus Pharma Inc (LIMN) saw a 15.36% incre", "url": "https://ng.investing.com/news/stock-market-news/form-4-liminatus-pharma-inc-for-14-july-93CH-2599673", "source_name": "Investing.com Nigeria", "published_at": "2026-07-14T22:52:00", "published_display": "14 Jul 2026 22:52", "sentiment": "positive", "sentiment_pct": 58, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Liminatus Pharma (LIMN) investors Valetudo and Chris Kim report 9.6M-share stake", "summary": "", "url": "https://news.google.com/rss/articles/CBMiygFBVV95cUxOYWJyVzJFenlzZ0xoNkx5T0tqZTN5UU1BdVgwcUNzVUNDMnpDTlZvd0g5QUlpNnBoRzR5MVVHQUhJR0M2M1I5dWIzMk5jWnQ1b2VncGVhLXJ6b19qMWRMSG5CSVcxUjBaR1Z1VEo2Z0kwbDZaZUoyQ3FyZWxLZGttZ0JaOTRTMnZycDNxcWRoTk90NVhWQ1VEOTN3TFBNMHlobDJaV2F5YWREOXM0YmxzY0NnNzl1blhOT3lpRGxWTm4zVFVYUTZCOFZ3?oc=5", "source_name": "Stock Titan", "published_at": "2026-07-14T21:36:44+00:00", "published_display": "14 Jul 2026 21:36", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Form DEF 14A Liminatus Pharma Inc For: 13 July By Investing.com", "summary": "This article reports on the filing of Form DEF 14A by Liminatus Pharma Inc. on July 13th, as published by Investing.com. It indicates Liminatus Pharma Inc. (LIMN) stock is down 8.30%. The content is brief, primarily acting as an announcement of the regulatory filing and its date.", "url": "https://ng.investing.com/news/stock-market-news/form-def-14a-liminatus-pharma-inc-for-13-july-93CH-2596939", "source_name": "Investing.com Nigeria", "published_at": "2026-07-13T13:50:00", "published_display": "13 Jul 2026 13:50", "sentiment": "negative", "sentiment_pct": 31, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Teleflex Incorporated (TFX) Stock Analysis: Unpacking a 32.3% Revenue Growth in the Healthcare Sector", "summary": "", "url": "https://news.google.com/rss/articles/CBMi4gFBVV95cUxPQ3B5MlVsTlBhcXdmUVllazV2SWFHTmRudHVNdFY3RUYtR1FTXzNIV1VYODF0bTMyVThkOE1LZC11TGN2dUxBZzRPTDQxUDVDdF9PWW5VUk1rZVJkdXRjbTQ2MU1wa3BtejZ5NUhWY1dQLUZLS3duak1fMzIxcnNwUmc4X3N5Q1JXMFNQY1J0ZVd5aHF4NHVUQkpnNlNUU1VWcVljNjhGbkFicUNyOXktR0lZWkVxT09oU0VQZnZObG5RMkJDWHh4czRrUktNZFNrZVhKWnF1YTZ2ZmVzTG14WG1n?oc=5", "source_name": "DirectorsTalk Interviews", "published_at": "2026-07-13T09:24:17+00:00", "published_display": "13 Jul 2026 09:24", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to sales forward of Liminatus Pharma, Inc. \u2013 NASDAQ:LIMNW", "summary": "The article displays the \"Price to sales forward\" metric for Liminatus Pharma, Inc. (NASDAQ: LIMNW) within the TradingView platform. It shows that there are no trades and the market is closed for this specific financial metric. The content highlights the navigation path to this i", "url": "https://www.tradingview.com/symbols/NASDAQ-LIMNW/financials-statistics-and-ratios/price-sales-fwd/", "source_name": "TradingView", "published_at": "2026-07-12T13:10:47", "published_display": "12 Jul 2026 13:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to sales forward of Liminatus Pharma, Inc. \u2013 NASDAQ:LIMN", "summary": "The article displays the \"Price to sales forward\" metric for Liminatus Pharma, Inc. (LIMN) on the Nasdaq Stock Market. It indicates that the market was closed at the time of viewing, with no trades observed. The content primarily shows the financial information section for the co", "url": "https://www.tradingview.com/symbols/NASDAQ-LIMN/financials-statistics-and-ratios/price-sales-fwd/", "source_name": "TradingView", "published_at": "2026-07-11T23:10:32", "published_display": "11 Jul 2026 23:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Enterprise value to EBIT forward of Liminatus Pharma, Inc. \u2013 NASDAQ:LIMN", "summary": "This article focuses on the enterprise value to EBIT forward metric for Liminatus Pharma, Inc. (NASDAQ: LIMN). It appears to be a financial data point provided on a trading platform, likely TradingView, indicating a specific financial ratio for the company's valuation.", "url": "https://www.tradingview.com/symbols/NASDAQ-LIMN/financials-statistics-and-ratios/enterprise-value-ebit-fwd/", "source_name": "TradingView", "published_at": "2026-07-09T20:13:18", "published_display": "09 Jul 2026 20:13", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Liminatus Pharma, Inc. Class A Common Stock (NASDAQ: LIMN) Stock Price, News & Analysis", "summary": "This article provides an overview of Liminatus Pharma, Inc. (NASDAQ: LIMN) stock, including its current price, basic fundamental data, and a link to charting information. It highlights the stock's last updated price of $0.123 and discusses its low trading volume. The page also of", "url": "https://kalkine.com.au/company/nasdaq-limn/", "source_name": "Kalkine", "published_at": "2026-07-09T20:13:18", "published_display": "09 Jul 2026 20:13", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Number of employees of Liminatus Pharma, Inc. \u2013 NASDAQ:LIMNW", "summary": "This article focuses on Liminatus Pharma, Inc. (NASDAQ: LIMNW) and specifically addresses the number of its employees. It appears to be a stub or data-point-oriented page from TradingView, which aggregates financial data for the company.", "url": "https://www.tradingview.com/symbols/NASDAQ-LIMNW/financials-statistics-and-ratios/number-of-employees/", "source_name": "TradingView", "published_at": "2026-07-08T13:11:04", "published_display": "08 Jul 2026 13:11", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Enterprise value to EBITDA forward of Liminatus Pharma, Inc. \u2013 NASDAQ:LIMN", "summary": "This article provides financial data for Liminatus Pharma, Inc. (NASDAQ: LIMN), focusing on its enterprise value to EBITDA forward metric. The content highlights the company's stock market information on Nasdaq and lists various financial and community services offered by Trading", "url": "https://www.tradingview.com/symbols/NASDAQ-LIMN/financials-statistics-and-ratios/enterprise-value-ebitda-fwd/", "source_name": "TradingView", "published_at": "2026-07-08T01:10:35", "published_display": "08 Jul 2026 01:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "4.37M Liminatus (NASDAQ: LIMN) shares moved in entity transfer", "summary": "Valetudo Therapeutics LLC, a ten percent owner of Liminatus Pharma (NASDAQ: LIMN) and associated with CEO Chris Kim, transferred 4,373,603 shares of common stock to Ewon Comfortech Co., Ltd. for no consideration. Valetudo retains voting power over these transferred shares through", "url": "https://www.stocktitan.net/sec-filings/LIMN/form-4-liminatus-pharma-inc-insider-trading-activity-a09731f15256.html", "source_name": "Stock Titan", "published_at": "2026-07-07T17:11:04", "published_display": "07 Jul 2026 17:11", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Ewon Comfortech discloses 5.5M shares in Liminatus Pharma (NASDAQ: LIMN)", "summary": "Ewon Comfortech Co., Ltd. has disclosed a beneficial ownership of 5.5 million shares, representing 10.9% of Liminatus Pharma Inc. (NASDAQ: LIMN) common stock, according to a Schedule 13G/A filing. The filing indicates Ewon Comfortech holds sole dispositive power over all 5.5 mill", "url": "https://www.stocktitan.net/sec-filings/LIMN/schedule-13g-a-liminatus-pharma-inc-amended-passive-investment-disclo-0a686970482a.html", "source_name": "Stock Titan", "published_at": "2026-07-07T05:10:35", "published_display": "07 Jul 2026 05:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Liminatus Pharma (LIMN) completes InnocsAI acquisition with large convertible preferred stake", "summary": "Liminatus Pharma has completed its acquisition of InnocsAI by restructuring the merger consideration to include both common stock and a significant stake in new Series A Non-Voting Convertible Preferred Stock. This strategy allowed the deal to close before obtaining full stockhol", "url": "https://www.stocktitan.net/sec-filings/LIMN/8-k-liminatus-pharma-inc-reports-material-event-e74c8b54791f.html", "source_name": "Stock Titan", "published_at": "2026-07-07T05:10:35", "published_display": "07 Jul 2026 05:10", "sentiment": "negative", "sentiment_pct": 34, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 96, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to earnings forward of Liminatus Pharma, Inc. \u2013 NASDAQ:LIMN", "summary": "This article provides the \"Price to earnings forward\" value for Liminatus Pharma, Inc. (NASDAQ: LIMN). It indicates that the value is currently not available, with no trades recorded. The content seems to be a placeholder or a very early stage financial data page for the company ", "url": "https://www.tradingview.com/symbols/NASDAQ-LIMN/financials-statistics-and-ratios/price-earnings-fwd/", "source_name": "TradingView", "published_at": "2026-07-07T03:40:41", "published_display": "07 Jul 2026 03:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Form 4 Liminatus Pharma Inc For: 6 July By Investing.com", "summary": "This article reports on a Form 4 filing for Liminatus Pharma Inc which took place on July 6th. Form 4 filings are regulatory documents that must be filed with the U.S. Securities and Exchange Commission (SEC) whenever there is a material change in the holdings of company insiders", "url": "https://ng.investing.com/news/stock-market-news/form-4-liminatus-pharma-inc-for-6-july-93CH-2587705", "source_name": "Investing.com Nigeria", "published_at": "2026-07-06T22:04:00", "published_display": "06 Jul 2026 22:04", "sentiment": "negative", "sentiment_pct": 29, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to book forward of Liminatus Pharma, Inc. \u2013 NASDAQ:LIMN", "summary": "", "url": "https://news.google.com/rss/articles/CBMinAFBVV95cUxPbC12d1BpMWc2cTJ3Y3NYREVIWm5yUjFCLXplUmJfY2FCalZCUk9tRzFteExURUVjNXJYYXM2aUZILVpzTVNWZnVYMVQ5MFJHUDZobmp4RnlDa0FnZjE4b3MzaUVNOXg0ZFlSaHJXSDZfVS1kcF85VlBuTE9VUjdMVEtFb3UyWVAxblpXQTFWa0F6MjIxRGlvc3FwaHU?oc=5", "source_name": "TradingView", "published_at": "2026-07-05T23:39:13+00:00", "published_display": "05 Jul 2026 23:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Tenet Healthcare Stock Jumps As Analysts Hold Buy Ratings Into Earnings", "summary": "", "url": "https://news.google.com/rss/articles/CBMiiAFBVV95cUxNYzlxZUxqQXJsWHRaUDE4SE1xeXUySXpBalJOamFXdlpnOHdQU25fTVFSdGZlcENQX2tLU2ljMXlvNW8xSnFNcHhsYnhJZURQSWNueTR4cVItWVdxbXFOeDNWYVRfOG9rWGpBNUUwT2lBSHVkcFdMdnhEUzdycnczUms3a3dzSDk5?oc=5", "source_name": "timothysykes.com", "published_at": "2026-07-04T07:00:00+00:00", "published_display": "04 Jul 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "LIMN - Liminatus Pharma Inc Options", "summary": "This article provides a detailed financial overview of Liminatus Pharma Inc. (LIMN), including its market capitalization, income, sales, key valuation ratios, and stock performance metrics. It covers various operational and financial statistics, such as insider and institutional ", "url": "https://finviz.com/stock?t=LIMN&ty=oc&p=d&b=1", "source_name": "Finviz", "published_at": "2026-07-04T04:09:03", "published_display": "04 Jul 2026 04:09", "sentiment": "positive", "sentiment_pct": 60, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Biotech Pre-Market Pulse: LIMN, TENX, ELTX Swing Big", "summary": "Several biotech companies are showing significant gains in pre-market trading, indicating early momentum for the day. Liminatus Pharma (LIMN), Tenax Therapeutics (TENX), and Conexeu Sciences (CNXU) are among the leading gainers. The article details the top 10 pre-market biotech s", "url": "https://www.rttnews.com/3664349/biotech-pre-market-pulse-limn-tenx-eltx-swing-big.aspx", "source_name": "RTTNews", "published_at": "2026-07-02T13:41:11", "published_display": "02 Jul 2026 13:41", "sentiment": "positive", "sentiment_pct": 68, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "12 Health Care Stocks Moving In Thursday's Pre-Market Session", "summary": "This article lists 12 healthcare stocks experiencing significant movement in Thursday's pre-market session. It details both gainers like Liminatus Pharma (NASDAQ:LIMN) and Stablecoin Development (AMEX:SDEV), and decliners such as Elicio Therapeutics (NASDAQ:ELTX) and Beyond Air (", "url": "https://www.benzinga.com/trading-ideas/movers/26/07/60241536/12-health-care-stocks-moving-thursday-s-pre-market-session", "source_name": "Benzinga", "published_at": "2026-07-02T11:41:11", "published_display": "02 Jul 2026 11:41", "sentiment": "positive", "sentiment_pct": 75, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Why Tenet Healthcare (THC) Stock Is Up Today", "summary": "", "url": "https://news.google.com/rss/articles/CBMipgFBVV95cUxNTGpMSWYxM2M3RmxZNHFVMm5pTnNfeTZKNzNiWHFJRTBkUDYtMWJaOFB0ZUVKYldFclQ2WFdscFJKTjdHS25XZVpMRE9CRUlSU3NDS3hKTUtaamxpREN2LTAyc3AtdWdTZlhzZ3kzYmEtMEI5QjVGZ0VVdFN2R0dKUWh2Vm9FelByMUU5N0tXQk5OeU5ZZndqekVNeEJVbHVZVTNUdmFB?oc=5", "source_name": "TradingView", "published_at": "2026-07-02T07:00:00+00:00", "published_display": "02 Jul 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Press Release: Liminatus Pharma Amends Definitive Merger Agreement With InnocsAI to Expand Oncology Cell Therapy Pipeline", "summary": "Liminatus Pharma has amended its definitive merger agreement with InnocsAI, acquiring an exclusive global license for InnocsAI's AI-driven oncology cell therapy programs. This strategic move is expected to expand Liminatus's pipeline, particularly in areas like breast cancer and ", "url": "https://www.moomoo.com/news/post/72285085/press-release-liminatus-pharma-amends-definitive-merger-agreement-with-innocsai", "source_name": "Moomoo", "published_at": "2026-07-01T14:41:11", "published_display": "01 Jul 2026 14:41", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Liminatus Pharma Amends Merger Deal With InnocsAI", "summary": "", "url": "https://finance.yahoo.com/markets/stocks/articles/liminatus-pharma-amends-merger-deal-112501129.html", "source_name": "MT Newswires", "published_at": "2026-07-01T11:25:01+00:00", "published_display": "01 Jul 2026 11:25", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 85, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Form PRE 14A Liminatus Pharma Inc For: 30 June By Investing.com", "summary": "This article announces the filing of Form PRE 14A by Liminatus Pharma Inc for June 30. It is a brief, factual update from Investing.com, providing basic financial market data alongside the news. The filing itself is not detailed, but the article contextualizes it within a broader", "url": "https://ng.investing.com/news/stock-market-news/form-pre-14a-liminatus-pharma-inc-for-30-june-93CH-2579596", "source_name": "Investing.com Nigeria", "published_at": "2026-07-01T03:39:19", "published_display": "01 Jul 2026 03:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Liminatus Pharma Amends Definitive Merger Agreement with InnocsAI to Expand Oncology Cell Therapy Pipeline", "summary": "Liminatus Pharma, Inc. has amended its definitive merger agreement with InnocsAI LLC, an oncology biotechnology company, to strategically expand its oncology cell therapy pipeline. The re-structured transaction, now valued at approximately $320 million, is expected to close on Ju", "url": "https://www.manilatimes.net/2026/07/01/tmt-newswire/globenewswire/liminatus-pharma-amends-definitive-merger-agreement-with-innocsai-to-expand-oncology-cell-therapy-pipeline/2376263/amp", "source_name": "The Manila Times", "published_at": "2026-07-01T02:36:00", "published_display": "01 Jul 2026 02:36", "sentiment": "positive", "sentiment_pct": 76, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Liminatus amends InnocsAI merger, closing set for July 2", "summary": "Liminatus Pharma, Inc. has amended its merger agreement with InnocsAI LLC, with the closing now expected on July 2, 2026. The revised terms involve InnocsAI equity holders receiving Liminatus common stock and non-voting convertible preferred stock, valued at approximately $320 mi", "url": "https://www.investing.com/news/company-news/liminatus-amends-innocsai-merger-closing-set-for-july-2-93CH-4768848", "source_name": "Investing.com", "published_at": "2026-06-30T21:39:28", "published_display": "30 Jun 2026 21:39", "sentiment": "negative", "sentiment_pct": 19, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Liminatus pushes $320M InnocsAI merger to July 2 close", "summary": "Liminatus Pharma (Nasdaq: LIMN) has amended its definitive merger agreement with InnocsAI, restructuring the $320 million transaction to close on July 2, 2026, before obtaining stockholder approval. InnocsAI equity holders will receive Liminatus common and non-voting convertible ", "url": "https://www.stocktitan.net/news/LIMN/liminatus-pharma-amends-definitive-merger-agreement-with-innocs-ai-6el3l58pczox.html", "source_name": "Stock Titan", "published_at": "2026-06-29T18:10:47", "published_display": "29 Jun 2026 18:10", "sentiment": "positive", "sentiment_pct": 60, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Cooper Companies Stock: Is COO Underperforming the Healthcare Sector?", "summary": "", "url": "https://news.google.com/rss/articles/CBMiqwFBVV95cUxPWkdoUDRJdkh3QndoZ3J2OHBvOEJlMUFEYjc1X3pLZGFXUlJ6eS1iNXhpYzNyd1NSZGxPOUdDM0xnZW9RcS1kdWNwR0xydVFVcEFGVmhfWWF5SFhYTmR5dXM0cTRIUENtbTc5bUpuNTNZQ0h0QWhMbnZDdGpfYjRWM2c3SWlCOHVJYTVoaUdDYnk2cTRKWWZTZHFvXzZDMTFmOGRUUUhyX3J6RUE?oc=5", "source_name": "Market source", "published_at": "2026-06-16T07:00:00+00:00", "published_display": "16 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Puma Biotechnology Stock Rises 19% in 3 Months: Here's Why", "summary": "", "url": "https://news.google.com/rss/articles/CBMinwFBVV95cUxObTdhSlJXM3BhWXRZM1NuWVBvNFZKS09CUkMyLV93TEdVQUdycktzUG5tRnFwUFlabkluMDFsMUpYYzFiQUxPWVdwczhNeVVjN0Rvc2k3VUZuS3NlTmEycHVpMGV1eDhnaEZkQ1JCaHVkcVZnMGd6Q2xzYnVpZV9tVVRLcjZnaWd0NlRhSnRENWIxSzhBQkd5WnRxVXN4dkk?oc=5", "source_name": "Market source", "published_at": "2026-06-11T07:00:00+00:00", "published_display": "11 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Liminatus Pharma Enters Into Warrant Exercise Transaction for $1.9 Million in Gross Proceeds", "summary": "", "url": "https://finance.yahoo.com/markets/stocks/articles/liminatus-pharma-enters-warrant-exercise-123000210.html", "source_name": "GlobeNewswire", "published_at": "2026-06-03T12:30:00+00:00", "published_display": "03 Jun 2026 12:30", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Existing investors put $1.9M into Liminatus in 18\u00a2 warrant deal", "summary": "", "url": "https://news.google.com/rss/articles/CBMivAFBVV95cUxObjhnY1FkWHVWVkFJNWxMT25BU1hWMkliNFJnYXNuWmVZNFUyUm95ZGY0MTJvU19vUW9YOGcyNG9nUzIwQjZ0N1hqMlJQRWc1Tzh6bDd1eXRYZi1od2xKUW5DeERBcHM4cHgxVWpPZkhYQVVJX01MbDJCQkh2eURJcDRveGdpclFib1oxM3N0NXJ1RHh1elNnS3pGN1htQjZKRTY5U0FGRm9yTjZZTzdyVnhXUndyN1pnS2hFcg?oc=5", "source_name": "Stock Titan", "published_at": "2026-06-03T07:00:00+00:00", "published_display": "03 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "UNH stock jumps on Q1 earnings beat and raised guidance to $18.25+", "summary": "", "url": "https://news.google.com/rss/articles/CBMimAFBVV95cUxPTEprdzNMNGZxdkg5Wll5MTlvS1dheXQybm14TERTcGVzcHQzY0llOEpTa0dpZ1hGdHVyNWZ2cFFiWmZRdkl1aUp4YVlTMVJxSDRzaEdzRFB1cW93QzdhSmNxcEZDMWhGX2F0ODJFcjY1Mk1kMVhLNnVJSUhVMHZpRjRtTHo2cXBvbVJ3a05SWlJNMUdrSzFPbA?oc=5", "source_name": "eciks.org", "published_at": "2026-05-26T07:00:00+00:00", "published_display": "26 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 84, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Liminatus Pharma, Inc. Receives Nasdaq Delisting Notice Following Non-Compliance with Market Value Requirements", "summary": "", "url": "https://news.google.com/rss/articles/CBMi3AFBVV95cUxQYXdNZFdFaUhJaGhmOV9LYXhaS055ZzBXNlhPaFVjOW1uNHd6bndtM1NQX2hzSFgxem5RcE9aYVZXdzZwRll4UUtzbHYwbXVDVVJ6UkdMUnpPdjQ4QmhaY1FNLTdtUFRaRXJnWGhFT1V5MFJ6dXlkbjVaNllkQnoyUE9xUHQ3c0lKT3pQOC1SeXVkUjktaUtCbklhTVNWU0pRR25oTFNSTldXQS1NazNJaFFvSUJ1akhObmszbnRHeGtmbTg1TVUtbU41THZuWVhCaVM3c0VGVlRuRzU5?oc=5", "source_name": "Quiver Quantitative", "published_at": "2026-05-22T07:00:00+00:00", "published_display": "22 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Liminatus Pharma faces Nasdaq delisting after compliance failure By Investing.com", "summary": "", "url": "https://news.google.com/rss/articles/CBMiwwFBVV95cUxOeWhITjdGNV96TTZrRkJRU2hDYjJhTmZCNG1KS25tZnJ6bnNmX3oxMEsyNXpNdXFuSXVPeGE3QXR6d0ZkMVFRaHU5VDdMbXljbzlvaU92YjlYMURzcXBpb2VKeVZ0c1BhdUNhYUJfWkRzN2d2Wld0RzdYRTlUcmpfcHU2RGhKdWR1aXAtN2Q1a3FJQ0doeXg1cTk4V0w4bXNoNGhKWlVJWHVOTWh5OVIyc3lrd2dUMnNZTkZ6M2FjcTUxSEU?oc=5", "source_name": "Investing.com Nigeria", "published_at": "2026-05-22T07:00:00+00:00", "published_display": "22 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Liminatus Pharma Announces Nasdaq Delisting Notification", "summary": "", "url": "https://finance.yahoo.com/markets/stocks/articles/liminatus-pharma-announces-nasdaq-delisting-002800076.html", "source_name": "GlobeNewswire", "published_at": "2026-05-22T00:28:00+00:00", "published_display": "22 May 2026 00:28", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Trending Stocks Today | Liminatus Pharma Surges 62.75%", "summary": "", "url": "https://news.google.com/rss/articles/CBMimAFBVV95cUxQeDZ3djRLYU9mUjRkZkJXSE01X1VEalJyOWFYaFBoOXBRWFlkTm5WZjNBaVZKaHRnRmlKc2ZHd3pBVWJfVEJ4eUlTeDE3cEZYRDVSWFoxRERBUEx5R3MzM1VVY2VWd25jbUIzOV9kTngxeGh6dXYzcjBNUHBQVUxNWFdnaDRwYjVSWXZNNHpYOV9Fa2RYc3A1NQ?oc=5", "source_name": "Moomoo", "published_at": "2026-05-21T07:00:00+00:00", "published_display": "21 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Cancer biotech Liminatus lines up $320M deal for new cell therapies", "summary": "", "url": "https://news.google.com/rss/articles/CBMivwFBVV95cUxPd05HR3VqSHo0TnRJd2NqWS14ZmsxU2pFMGZxQ004NVRxTXVudmhkX2dpRUZLbFJzZ1kyMXNrRnNCV3A0Z29SSm5hNkRiSG5DUVAwSG5ieGdsUUlybVhFdXcwX2tTTXNyanJ2QXBmTG1uMFZvLVJiMnJKWDgyeDJTc25fWlJFeEZSNXgtR01OLUcyRjh5RkYzWE5TYmktNGkwUm02YVNXVW5peFRWRGpKZG0wZlplU25XR3p4X1Q3MA?oc=5", "source_name": "Stock Titan", "published_at": "2026-05-21T07:00:00+00:00", "published_display": "21 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Liminatus Pharma Is Trending Overnight \u2014 Here's Why LIMN Stock Surged Over 79% In After-Hours Session", "summary": "", "url": "https://news.google.com/rss/articles/CBMi6gFBVV95cUxPeWdyd09vdXhDTFdUYXV3SG0wZGtPRmFWR1AzTW1OemRGRlhsT0VoNFNRSEdrWGJLdGNpR09XLVowWG1KdVpHalpiaXNwLWtjOTBJTFctZVBMZktOVkpWbjc2WkJpQVY5d3M4ZVhZVFdOaGtlR1R2UGliNjNaZy03VkwwSkdXalNsZU5rNzVWNUtUbk5zTWM4NkNocnZCSzlWQ29ybHZ3eHVFaEUwVnpTZ2J4R2lTUFFVclloaGhpNFMxS1JNNmVyZ2JPWjdXTzNYUzdwZHhDbUFOVmpkZ3h4ZHpucVA3VWlXLUE?oc=5", "source_name": "Benzinga", "published_at": "2026-05-21T07:00:00+00:00", "published_display": "21 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Liminatus Pharma faces Nasdaq delisting after market value shortfall", "summary": "", "url": "https://news.google.com/rss/articles/CBMinwFBVV95cUxOTURCcG1UY1JheVlhTWZuNElsNzRGLVYwaGNfdmxsUkRiSmhaTHlHUzIyRkVyU3JaS3R5c0VPU2dZYlZhZVpYcUpGc2J2YXc2UHdGUjhtYXVuZ2gtaUgwS3FNSGNpbGxVZGxMeFktZFYyWkx2LW02S2o0YzctVUlEM2cweGpfaXAzOHJsVm93U3dyNlVZMFBLNGxNTlZmV2M?oc=5", "source_name": "Stock Titan", "published_at": "2026-05-21T07:00:00+00:00", "published_display": "21 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Liminatus Pharma (LIMN) plans all-stock InnocsAI merger with CAR-T pipeline", "summary": "", "url": "https://news.google.com/rss/articles/CBMirgFBVV95cUxPT21KRjM0Zm02cEpwVkQwZWQ3Z1NPTExjZFlMZ1ZnZDVfV3FpVlVYalZmeG1KYlVtQkQ0NFhDN3RVMU5GQXp2aW5ScF82N2N0U3kzcThJc3dIYnJOeW1YbzljalFpX1JnMGpLQXJ0T09sYndTZHNzM2FaZUdXZGJLMzR0ZnJMTkVpR1JiVjRRcmx3d1NCNFVqVS12TXRpdEhiUHhVOXZjN2hTU28tZHc?oc=5", "source_name": "Stock Titan", "published_at": "2026-05-20T07:00:00+00:00", "published_display": "20 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Puma Biotechnology, Inc. (NASDAQ:PBYI) Analysts Are Pretty Bullish On The Stock After Recent Results", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Puma Biotechnology Stock Declines More Than 9% in a Month: Here's Why", "summary": "", "url": "https://news.google.com/rss/articles/CBMijAFBVV95cUxNTTJZRVF4TFNBb3BhMW9VUnBnMVZhenZLNlZJY3Ryc3pGZ3dhZXBDY3pId0I5NFdmVTdiR2EyNXNBZFFuQ1M2M3pUTlRZdXJkbGxaT29mWm4wTG5fU2RtV1hIZWRwZUVNb3BEbTZKX3NPRV9mZVpiY3JBZDdMSDRveW1Jb0lIVmRKLVlidA?oc=5", "source_name": "Market source", "published_at": "2026-03-18T07:00:00+00:00", "published_display": "18 Mar 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Why Did Puma Biotechnology's Stock Plummet Despite Beating Q4 Estimates", "summary": "", "url": "https://news.google.com/rss/articles/CBMiqgFBVV95cUxQUEQ4TXY0R1lWMTJIcEJySm5iaEl1UkJ6TDMxcUtQYVl3UmxYdlJnaElpdlJDLU0xTTRvT0dsellqX21Tc3lxWW9IbWxHMnFBZGlxajdnUUU2OTNVY0l3NUh0OExMUENwWGxqY1d5dXV3YmRDZm9IRzc1c3FjbUh2cGxvdEJMZ25lYXdjSUliZ0txSjVFOHJhUXNTajBLeVV0M3B4dDk4V3dfQQ?oc=5", "source_name": "Kavout | AI", "published_at": "2026-02-28T09:53:07+00:00", "published_display": "28 Feb 2026 09:53", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Cava Stock Surges 24% After Upbeat Earnings and Strong 2026 Outlook", "summary": "", "url": "https://news.google.com/rss/articles/CBMingFBVV95cUxQcV9JR0t0QUpQRWhQU0JxOGZld2wxZmNTb0ZoV05TZVBhUjRxRGF2Zno5YWRaVkxKRzNsbk8yY01fdk95S09xcV9aT0FFS1A3Zzhfd0ZLVVVRVU1jY1BiZmZ6T0drMjlfLVNXMTVBZjdtWXdNTEdHTEc2ejFqX1lTREs3eXBhbWRjaUhRWHJMZlYxWGFGZnYwOUJ2Mm9uQQ?oc=5", "source_name": "TIKR.com", "published_at": "2026-02-26T08:00:00+00:00", "published_display": "26 Feb 2026 08:00", "sentiment": "positive", "sentiment_pct": 82, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Vir Biotechnology Stock Skyrockets 65% on Positive Prostate Cancer Treatment Trial Results", "summary": "", "url": "https://news.google.com/rss/articles/CBMivwFBVV95cUxNeEtXZ1k1WGctLWZuX0tYZE5SLWN4MU5KUktLV3NobzVheFpoMkZhdFJrWTdNelAwWGxYZUswazZtMWFUaXEzY3k0QnI0TW9IMGc2UTNzUlNmR1JxZG1JbEpQM0N3N1p4blRjaGdvMExoZzJOYWF3Tk5hajJCTlprZ3dESTVEd0Y4TXhvcElNR3Bqemd3RmNKcGxwa2dSU2phak9paE53c0t3dVFVeGZic2liZ1I0UU80TEM2WUNlOA?oc=5", "source_name": "TIKR.com", "published_at": "2026-02-25T08:00:00+00:00", "published_display": "25 Feb 2026 08:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}], "industry": [{"title": "Q1 Earnings Highs And Lows: Natera (NASDAQ:NTRA) Vs The Rest Of The Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMilAFBVV95cUxNYmZ3aHMyMjBuNmlEUGN6NWZBZV85cEFWNndJaVNoNEVYNk84MlNKRXJ0RXpRQl9wN1RsekhxM3loY1RRNDJhTnVremtReHhLQWVHS053VzRBUTduSkdqRGt1YkxMMThqZHoydElPX1Zfd3hEMi15VlRwRGRvZ2JqRDFneVVxN0JCYzQ4QlV5TTBEOWx3?oc=5", "source_name": "Market source", "published_at": "2026-07-16T18:49:22+00:00", "published_display": "16 Jul 2026 18:49", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Unpacking Q1 Earnings: Incyte (NASDAQ:INCY) In The Context Of Other Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMinAFBVV95cUxOZExLRk1BSFNPMnpMdEFEWjNtbWlkZUQ1aHJHZEtMZHJHZWZDZUI0ck1FM2JqWG9ncDRSNGxEWHZLemZualBEY3BVVzdiUmZiVmxqMFdnbEczbEpvTFBscnA3YVVMWmQ3TkFsVjBDZzl6VEZQanh1UkRaS2hiRTNPbGFwajRSV1A1amFKcnFhcFVITHdydjJpblVRTWI?oc=5", "source_name": "Market source", "published_at": "2026-07-13T12:30:39+00:00", "published_display": "13 Jul 2026 12:30", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "There May Be Reason For Hope In Puma Biotechnology's (NASDAQ:PBYI) Disappointing Earnings", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-15T07:00:00+00:00", "published_display": "15 May 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Puma Biotechnology's (NASDAQ:PBYI) Conservative Accounting Might Explain Soft Earnings", "summary": "", "url": "https://news.google.com/rss/articles/CBMirgFBVV95cUxNZXcyN1VKc0J0RTFtSER6TGRSZm8xSWs2c0paem5paDd3V0J1cjF6ajhFb29tRFpUWWpxYUhzZjFkSXhYQ0lBNTVlbTdCRERpSXNjaGpDajFPOVlpRS1qV2xHMTRHS2pjVVBZMWFfNzItWE9FeENtQ2duMUxVQm5kOG41eVlrNUpObXp2VlhfekdhMVh2X0hjN3ZFZThZNUdWakFLUXJ4aFBVN2JyR2c?oc=5", "source_name": "Market source", "published_at": "2026-05-14T07:00:00+00:00", "published_display": "14 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Earnings Update: Here's Why Analysts Just Lifted Their Puma Biotechnology, Inc. (NASDAQ:PBYI) Price Target To US$5.00", "summary": "", "url": "https://news.google.com/rss/articles/CBMingFBVV95cUxPSUN3RjZYMEJ2VUdKQjJpRkZaUXRzM2NTa05WWmlmWHJnZDlJeUpTdFM5Wmk0SUhjclU2dldTZFIyRmZZeGJSNGM2SUNiSGJSYjh1VjYyR0hPZ2FJbWdsbHExYlhwMW1HRTZ0NUxwQzU1b2g4MGpwSHdoMkdIOUtqOXBBYk92LVk2cEFZMzVISjB3c04ydVBEYWw2cVVsdw?oc=5", "source_name": "Market source", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Q4 Earnings Highlights: Regeneron (NASDAQ:REGN) Vs The Rest Of The Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMirAFBVV95cUxNWW9GYm5uRzlBX2ZiZXA3RkdDXzJhaFd2N1ZwR21jaXhiRkZQSTNHT0hMaUFjSGl6VXZfOURKemF2bWlFS1hKTXBjZUw4amdVQ0I4QlVnNmFkY1VTQ25pUjBiZGNDUE9QdWdOZHAxV1I1ejN6UE9WdGpseUdrMVA5MXBXWXJmWDBkZUdWUkxpOURCdlZlbDlQR3M5cjAzaDFtakFNblRTa3c0Q1J6?oc=5", "source_name": "Market source", "published_at": "2026-04-25T07:00:00+00:00", "published_display": "25 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Biotechnology Stocks Q3 Results: Benchmarking Natera (NASDAQ:NTRA)", "summary": "", "url": "https://news.google.com/rss/articles/CBMiswFBVV95cUxPZzZDSEhwNlVYQU9kNXBMMU5ia0FTU0RxRlYwb0I1RERNODN4N0VwRFZWMUY4ODh3eWNkTkp0UERreFlSTllocGk4a2ZKcGlJVjQ4d1dXWlNnYTc5UlNMZm4wc2xITjRQVzhRb3Z5LXllQmhvUHNIaXB3LXk1RUw1WnRPam9wcVE1MXFxSmVzVF9MVmRyMWIwdVkxS1N3MUJZUzByLWxrVDlSSUk4QnNsXzJYbw?oc=5", "source_name": "Market source", "published_at": "2026-04-21T07:00:00+00:00", "published_display": "21 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "A Look Back at Biotechnology Stocks\u2019 Q4 Earnings: Incyte (NASDAQ:INCY) Vs The Rest Of The Pack", "summary": "", "url": "https://news.google.com/rss/articles/CBMi5gFBVV95cUxNWEtsYkktQkxQRHpTMHJOZzJaN09fT3R5aUpjZ0xEQTZXZGlCVUk0alZrVXhIRERNOW9feVJ1X0R4VUI2Q0FjUGIwTWpIRXE2dXpCLW9NdVdoSEE5b0JEM18wN2FQSGdXMDZfOGJ3STJPUmQ2VVBIbUQ5djhTZ01RTmpxLTdKRmdhN0U3RE52N0dEUzh4VFZ5c3dDd0ppZ1VYeGc0Mm5oQlU5TGJlQldpVHpoVjlhdXZ6ek0yaTBuQV9UUjNFT19kWFZ4QVViODkwN2ppOFRQU3lHQ1IxdXhrRkFGS3E0QQ?oc=5", "source_name": "TradingView", "published_at": "2026-03-29T07:00:00+00:00", "published_display": "29 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}], "sector": []}, "total_fetched": 91, "total_relevant": 65, "sentiment_summary": {"positive": 17, "negative": 6, "neutral": 42, "score": 53, "total": 65, "label": "Balanced news tone", "tone": "neutral"}, "classifier": {"primary_event": "general", "primary_label": "Market update", "confidence": 79, "events": [{"event": "general", "label": "Market update", "weight": 19.05, "count": 34}, {"event": "earnings", "label": "Earnings", "weight": 8.6, "count": 17}, {"event": "deals", "label": "Deals and strategy", "weight": 6.05, "count": 11}, {"event": "regulatory", "label": "Regulatory and legal", "weight": 1.1, "count": 2}, {"event": "guidance", "label": "Guidance", "weight": 0.55, "count": 1}], "positive_events": 17, "negative_events": 6}, "market_context": {"has_market_context": true, "latest_close": 0.12, "latest_week": "2026-07-17", "one_week_move": 7.5, "four_week_move": 3.2, "twelve_week_move": -37.9, "trend_signal": "0", "trend_label": "Trend inactive", "trend_tone": "negative", "market_dynamics": 1.336652, "market_dynamics_buy_signal": true, "relative_strength": -91.028238, "fair_value_gap": -95.5, "fair_value_label": "Below fair value", "fair_value_tone": "positive", "expectation_direction": "negative", "expectation_probability": 34.6154, "reaction_label": "Price confirming higher", "reaction_tone": "positive", "market_sentence": "+7.5% over one week, +3.2% over four weeks, trend inactive, and below fair value."}, "interpretation": {"label": "Price moving ahead of tone", "tone": "positive", "classification": "price_leads_news", "summary": "Price is moving more forcefully than the current news tone suggests.", "confidence": 61, "badges": ["Market Dynamics buy signal", "Value support"], "opportunities": ["Market Dynamics is showing a buy signal in the latest weekly context.", "Price is below fair value while news tone is not negative."], "risks": [], "event_label": "Market update", "sentiment_word": "balanced"}, "charts": {"sources": [{"label": "TradingView", "count": 11}, {"label": "Market source", "count": 9}, {"label": "Stock Titan", "count": 9}, {"label": "Investing.com Nigeria", "count": 6}, {"label": "Moomoo", "count": 3}, {"label": "Benzinga", "count": 3}, {"label": "GlobeNewswire", "count": 2}, {"label": "simplywall.st", "count": 2}], "tiers": [{"label": "Direct company coverage", "count": 57}, {"label": "Industry context", "count": 8}, {"label": "Sector context", "count": 0}], "events": [{"label": "Market update", "count": 34}, {"label": "Earnings", "count": 17}, {"label": "Deals and strategy", "count": 11}, {"label": "Regulatory and legal", "count": 2}, {"label": "Guidance", "count": 1}]}, "insights": [{"label": "Weighted tone", "value": "53/100", "tone": "neutral", "text": "Balanced news tone"}, {"label": "Market reaction", "value": "Price moving ahead of tone", "tone": "positive", "text": "Price is moving more forcefully than the current news tone suggests."}, {"label": "Primary event", "value": "Market update", "tone": "neutral", "text": "79/100 classification confidence."}, {"label": "Company focus", "value": "57", "tone": "positive", "text": "directly relevant articles"}, {"label": "Source quality", "value": "2", "tone": "positive", "text": "high-authority source matches"}, {"label": "Trend context", "value": "Trend inactive", "tone": "negative", "text": "+7.5% over one week, +3.2% over four weeks, trend inactive, and below fair value."}, {"label": "Latest direct headline", "value": "Neutral", "tone": "neutral", "text": "$Liminatus Pharma (LIMN.US)$"}], "updated_at": "2026-07-21T03:46:13.131450+00:00", "disclaimer": "Educational market research only. Not financial, investment, trading, tax, or legal advice."}